Bio Ventures Facing a Cash Crunch Get a Lifeline from National Growth Fund and U.S. Tailwinds
Increase in New Venture Investments in Bio and Medical Sectors
Selective Investment Strengthened on Expectations of Policy Funding
It appears that the inflow of funds into the bio and medical sectors in the domestic venture investment market is showing signs of recovery. With investment sentiment towards the U.S. bio industry improving and expectations rising for the National Growth Fund's disbursements in the healthcare sector, venture capital (VC) firms are once again turning their attention to bio-related investments. However, some point out that for investment sentiment to truly rebound, it will require not only the injection of policy funds but also the restoration of trust in exit markets, such as KOSDAQ.
According to the Korea Venture Capital Association (VC Association) on July 2, new venture investments in the bio and medical sectors amounted to KRW 736 billion from January to May this year, an increase of 89.6% compared to KRW 388.2 billion during the same period last year. The share of bio and medical in total new investments—KRW 3.7236 trillion—was 19.8%, making it the second largest after ICT services at 26.6%.
Policy Funds and U.S. Positive Sentiment Drive Recovery in Investment Sentiment
Until recently, the domestic bio industry faced an investment winter. Investment sentiment froze following clinical failures of highly anticipated new drug candidates and a series of incidents involving some listed companies. Even large asset managers were unable to make follow-on investments, leading to many cases where valuations were slashed by more than half.
Recently, however, the atmosphere appears to be turning positive, supported by the expansion of policy funds. The National Growth Fund included the healthcare sector in its investment scope for the second mega-project, and Ligachem Bio, a developer of antibody-drug conjugates (ADC), was selected as a Track A direct investment target with a fund size of KRW 500 billion. This has heightened expectations that policy funds could flow into the entire healthcare sector, including new drugs, medical devices, and contract development and manufacturing (CDMO).
The head of a domestic VC firm commented, "A few years ago, the tightening of special listing requirements led to a contraction in the bio market, and now we seem to be seeing a base effect from that period. Not only the potential easing of listing requirements but also the government's initiative to revitalize the KOSDAQ market is fueling optimism."
Kim Choonghyun, a researcher at Mirae Asset Securities, stated, "Investments made by the National Growth Fund can increase investor interest and serve as an opportunity to refocus on companies’ fundamentals. Direct investments in individual companies represent a strategic choice at the national level, drawing the interest of institutional investors, while sub-fund investments can create a real supply-demand shift of around KRW 600 billion."
Global enthusiasm for bio investments is also noteworthy. In the first quarter of this year, global pharmaceutical and bio mergers and acquisitions (M&A) exceeded USD 65 billion, marking the largest quarterly performance since 2020, with 16 mega-deals valued at over USD 1 billion each. The U.S. biotech exchange-traded fund (ETF) XBI has surged over 100% since its low in April last year, demonstrating strong performance.
"Key to Actual Recovery: Commercialization and Exits"
There are also projections that the gap between Korea and the U.S. will narrow in the second half of the year. Han Sanghee, a researcher at Hanwha Investment & Securities, explained, "The fact that U.S. bio is steadily rising, unlike the broader market index, is evidence of strong fundamentals and liquidity. Given the historically high correlation between the U.S. and Korean bio sectors, if perspectives on interest rates change, the gap between the two countries is likely to decrease in the latter half of the year."
Seo Geunhee, a researcher at Samsung Securities, observed, "The sluggish stock performance of domestic bio companies is not due to fundamental issues, but because market attention is elsewhere. Stocks with visible cross-border deal momentum—such as technology transfers, joint development, strategic investments, or M&As—will be the first to be re-evaluated."
However, some say that it will take more time for the bio industry to truly recover. An official from the domestic VC industry remarked, "Ultimately, the market needs to pay for and adopt these technologies. For trust to be restored in both KOSDAQ and overall bio venture investment, at least some of the companies listed based on technological prowess must achieve tangible commercialization results."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
He added, "In the long run, it is more important to have an environment where increasing numbers of companies deliver results and those that do not are quickly screened out, rather than simply propping up KOSDAQ. Since the bio sector's capacity and industrial infrastructure remain essentially unchanged, caution is needed to avoid a repeat of previous bubbles."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.